Avastus Preclinical Services purchased the assets of Vivisource on November 20th 2013 consolidated operations and has extended our offerings to include in vitro assay development and models of rare genetic diseases.  Our management team has over 125 years of cumulative experience working in the biotech/pharma industries and are uniquely suited to provide the highest quality research services, from initial biochemical assay development through proof-of-concept studies in animal models of human disease.